Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure

Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure: a Multicenter Prospective Observational Registry

The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates. The aim of this observational prospective registry is to evaluate if there is a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies with different EBPTs.

Study Overview

• Status: Recruiting
• Conditions: Sepsis; Systemic Inflammatory Response Syndrome; Critical Illness; Acute Kidney Injury
• Intervention / Treatment: Device: Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)

Detailed Description

The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. For most of these treatments, the extracorporeal removal of inflammatory mediators (via enhanced transmembrane clearance and/or selective/un-selective adsorption of bacterial toxins or inflammatory mediators) is already well established in the literature. Unselective cytokine removal is the main rationale for the use of EBPT, and it might explain the effect of these treatments on multiorgan dysfunction in critically ill patients. Indeed, an increment in hemodynamic stability and an improvement in the multiorgan dysfunction scoring system of treated patients are consistently observed in most of the studies available in the literature. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates.

Interestingly, the post-hoc analysis of large databases suggests that a specific subpopulation of patients, who are likely to benefit more than others from EBPT, could be identified in clinical practice. As an example, press releases from the Euphrates trial suggest that a specific range of baseline endotoxin activity assay might correlate with a positive long-term outcome in patients treated with Toraymixin cartridges. Nowadays, a personalized approach to extracorporeal therapy has been advocated as the only strategy capable of maximizing the clinical effect of EBPT and their impact on patient outcomes (i.e. precision medicine).

The identification of clinical characteristics correlated with positive outcomes during EBPT allows the implementation of specifically designed trials, focused on a well-defined cluster of patients.

The implementation of a large database encompassing the clinical/biochemical characteristics of patients undergoing EBPT is thus widely hoped for to enable the identification of a cluster of patients with specific features who most benefit from these treatments.

Although it is well known that only a clinical trial can formally assess the effect of EBPT on a specific clinical outcome, several drawbacks pose practical limitations to the implementation of a clinical trial in the critical care setting for this purpose. First, most European countries (and particularly Italy) do not allow the enrollment and randomization of non-competent patients (as critically ill patients formally are), due to ethical issues. Second, clinical trials are associated with very high costs. Third, the quality of results and conclusions deriving from post-hoc analysis of randomized clinical trials (often underpowered) may be qualitatively similar to those obtained from a very large database of patients observed during treatments performed according to the routine clinical practice.

As an example, COMPACT and COMPACT 2 trials, failed to demonstrate a significant effect of Coupled plasma-filtration adsorption (CPFA) on the outcome of critically ill septic patients, with the notable exception of specific subpopulations (e.g. those where an adequate volume of plasma was filtered and adsorbed). This conclusion was obtained through two highly-costly multicenter randomized clinical trials, prematurely halted due to ethical issues, using post-hoc analysis of a subgroup of an already limited sample size.

Nowadays, the identification of specific clusters of patients during EBPT is obtained by means of the implementation of a large web-based registry where a network of researchers can upload the clinical data of patients undergoing EBPT in line with the routine clinical practice of each single center. Taking into consideration the feasibility of the research (i.e. mainly related with the lack of critical ethical issues and the easy-to-use interface of web-platforms), these observation-based registries are inexpensive and effective tools able to identify specific clusters of patients within a very large sample size with widely heterogeneous clinical characteristics.

As an example, a web-based registry has been already implemented to describe the clinical effects of polymyxin-B based cartridges for endotoxin removal (EUPHAS 2 registry). Another one has been similarly implemented to describe the clinical effects of un-selective cytokine adsorption obtained with CytoSorb (CytoSorb registry).

Taking into consideration the fact that data on CPFA already exist and web-based registries are already available for aforementioned membranes, the aim of this project is to design and nationally promote a web-based registry designed for all remaining commercial membranes. In particular, an easy-to-use web-based platform will be made available for all centers that spontaneously adhere to this project.

Three main characteristics will distinguish this web-based registry when compared with the already available Euphas 2 and CytoSorb registries. First, it will also be available for smartphone and/or tablet applications; this characteristic will guarantee easy-to-use access and data uploading and enhanced compliance from clinical researchers. Second, it will not be confined to a simplistic registration of patients' data; it will instead also provide the clinician with clinical tools that might be helpful for patient management (e.g. automatic calculation of clinical scoring systems, ideal body weight, functions of mechanical ventilation, antibiotic adjustment according to renal function, etc.). All these tools will provide the clinician with real-time feedback; this web-based registry will provide a clear example of translational medicine and translational research, where data from clinical practice will feed a database for clinical research and, contemporaneously, the research tool will improve clinical practice, providing useful instruments for routine practice. Finally, this web-based registry will allow every center to instantaneously evaluate its results, providing a real-time basic statistic for every recorded variable (e.g. age at enrollment, main comorbidities, baseline serum creatinine, mortality rate, rate of multidrug resistant bacteria, etc.). This function may allow each center to continuously monitor outcomes and local practices, and will represent a major improvement when compared to already existing platforms in Italy, such as the Prosafe.

With this rationale, the research questions are:

• is there a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies (EBPT) with specific membrane?
• might some baseline variables be used to identify this subpopulation of "responsive" patients? In particular, may these indicators be employed to guide indications for EBPT , in order to personalize treatments and improve patients' long-term outcome?

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Gianluca Villa, MD; Phone Number: +393207615547; Email: gianluca.villa@unifi.it

Study Locations

• Italy
  • Brindisi, Italy, 72100
    • Recruiting
    • Ospedale A. Perrino
    • Contact: Luigi Vernaglione, MD; Phone Number: 0831 537648
    • Principal Investigator: Luigi Vernaglione, MD
  • Florence, Italy, 50100
    • Recruiting
    • Azienda Ospedaliero Universitaria Careggi
    • Contact: Gianluca Villa, MD; Phone Number: +393207615547; Email: gianluca.villa@unifi.it
    • Principal Investigator: Gianluca Villa, MD
  • Pavia, Italy, 27100
    • Recruiting
    • Fondazione IRCCS Policlinico San Matteo
    • Contact: Fiorenza Ferrari, MD; Phone Number: 3283751837; Email: fioreferrari@gmail.com
    • Principal Investigator: Fiorenza Ferrari, MD
  • Pistoia, Italy, 51100
    • Recruiting
    • Ospedale S. Jacopo
    • Contact: Alessandro Capitanini, MD; Phone Number: 3393332678; Email: drcapitanini@gmail.com
    • Principal Investigator: Alessandro Capitanini, MD
  • Prato, Italy, 59100
    • Recruiting
    • Ospedale S. Stefano
    • Contact: Filippo Becherucci, MD; Phone Number: +393286853053; Email: savignano1986@yahoo.it
    • Principal Investigator: Filippo Becherucci, MD
  • Reggio Calabria, Italy, 89124
    • Recruiting
    • Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
    • Contact: Graziella Marano, MD; Phone Number: 3471742807; Email: graziellamarano@libero.it
    • Principal Investigator: Graziella Marano, MD
  • Roma, Italy, 00168
    • Recruiting
    • Policlinico Universitario Fondazione Agostino Gemelli
    • Contact: Salvatore Lucio Cutuli, MD; Phone Number: 3483572090; Email: sl.cutuli@gmail.com
    • Principal Investigator: Massimo Antonelli, MD
  • Roma, Italy, 00189
    • Recruiting
    • Azienda Ospedaliero-Universitaria Sant'Andrea
    • Contact: Elisa Alessandri, MD; Phone Number: 3381023881; Email: ealessandri@ospedalesantandrea.it
    • Principal Investigator: Elisa Alessandri, MD
  • Torino, Italy, 10144
    • Recruiting
    • Ospedale Maria Vittoria
    • Contact: Giuseppe Rotondo, MD; Phone Number: 3400778463; Email: rotondo.giuseppe@outlook.it
    • Principal Investigator: Emilpaolo Manno, MD
  • Vicenza, Italy, 36100
    • Recruiting
    • Ospedale S. Bortolo
    • Contact: Claudio Ronco, MD; Phone Number: +390444753650; Email: claudio.ronco@aulss8.veneto.it
    • Principal Investigator: Claudio Ronco, MD
    • Sub-Investigator: Silvia De Rosa, MD
  • Firenze
    • Empoli, Firenze, Italy, 50053
      • Recruiting
      • Ospedale S. Giuseppe
      • Contact: Italo Calamai, MD; Phone Number: +383892840820; Email: italo.calamai72@gmail.com
      • Principal Investigator: Italo Calamai, MD
  • Lucca
    • Lido Di Camaiore, Lucca, Italy, 55049
      • Recruiting
      • Ospedale Versilia
      • Contact: Mariasole Baccelli, MD; Phone Number: 3383006667; Email: mariasole.baccelli@gmail.com
      • Principal Investigator: Mariasole Baccelli, MD
  • Milano
    • Rozzano, Milano, Italy, 20089
      • Recruiting
      • Humanitas Research Hospital
      • Contact: Massimilino Greco, MD; Phone Number: 3287063871; Email: massimiliano.greco@humanitas.it
      • Principal Investigator: Massimiliano Greco, MD
    • San Donato Milanese, Milano, Italy, 20097
      • Recruiting
      • IRCCS Policlinico S. Donato
      • Contact: Marco Vittorio Resta, MD; Phone Number: +393497752117; Email: marco.resta@grupposandonato.it
      • Principal Investigator: Marco Vittorio Resta, MD
  • Monza-Brianza
    • Monza, Monza-Brianza, Italy, 20900
      • Recruiting
      • Ospedale S. Gerardo
      • Contact: Roberto Rona, MD; Phone Number: +393494908214; Email: roberto.rona@libero.it
      • Principal Investigator: Roberto Rona, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All critically ill patients undergoing EBPT in the enrolling centers will be prospectively observed.

Although acute kidney injury will be mostly present among the enrolled population, it will be not strictly required as an inclusion criterion.

Similarly, although sepsis will be frequently observed, the systemic inflammatory state leading to multiorgan dysfunction and supported by these extracorporeal treatments might have several different etiologies, such as ischemia-reperfusion, severe acute pancreatitis, intoxication, etc. (i.e. "sepsis-like syndromes").

Description

Inclusion Criteria:

• critically ill patients in the ICU
• one of this EPB therapy:
• CRRT/IHD/Hybrid therapies for support//replacement renal function
• immunomodulation achieved by "high cut-off membranes", "endotoxins and/or cytokines adsorbent membranes" or by high-volume hemofiltration

Exclusion Criteria:

• patients treated only by Cytosorb® and/or Toraymyxin® therapies

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Critically ill patients; In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.

Device: Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT); Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of the subpopulation of critically ill patients that most benefits from EBPTs.	This subpopulation will be described using the baseline variables associated with a positive long-term patient's outcome. In particular baseline variables statistically associated through multivariable stepwise analyses with the patient's survival at hospital discharge will be identified and expressed with their Odds ratios, 95%CI and p-value	10 days after EBPT initiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of the over-time variation of clinical variables during EBPs	This over-time variation will be expressed, for each variable, as a percentage variation compared with the baseline value (at the EBPT initiation).	10 days after EBPT initiation

Collaborators and Investigators

• Sponsor: Careggi Hospital
• Collaborators: University of Florence
• Investigators: Principal Investigator: Gianluca Villa, md, University of Florence, Florence, Italy

Publications and helpful links

General Publications

• Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.
• Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014 Jun 11;15:218. doi: 10.1186/1745-6215-15-218.
• Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, Antonelli M; EUPHAS 2 Collaborative Group. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016 Dec;6(1):77. doi: 10.1186/s13613-016-0178-9. Epub 2016 Aug 8.
• Friesecke S, Trager K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM. International registry on the use of the CytoSorb(R) adsorber in ICU patients : Study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2019 Nov;114(8):699-707. doi: 10.1007/s00063-017-0342-5. Epub 2017 Sep 4.
• Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandiere M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015 Jun;41(6):975-84. doi: 10.1007/s00134-015-3751-z. Epub 2015 Apr 11.

Study record dates

Study Major Dates

• Study Start (Actual): July 16, 2019
• Primary Completion (Estimated): September 30, 2025
• Study Completion (Estimated): September 30, 2025

Study Registration Dates

• First Submitted: July 23, 2019
• First Submitted That Met QC Criteria: July 25, 2019
• First Posted (Actual): July 26, 2019

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 11, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Disease Attributes; Inflammation; Renal Insufficiency; Shock; Critical Illness; Acute Kidney Injury; Multiple Organ Failure; Systemic Inflammatory Response Syndrome
• Other Study ID Numbers: ARRT_aRIA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No